185 related articles for article (PubMed ID: 33547311)
1. The role of brain perivascular space burden in early-stage Parkinson's disease.
Shen T; Yue Y; Zhao S; Xie J; Chen Y; Tian J; Lv W; Lo CZ; Hsu YC; Kober T; Zhang B; Lai HY
NPJ Parkinsons Dis; 2021 Feb; 7(1):12. PubMed ID: 33547311
[TBL] [Abstract][Full Text] [Related]
2. Increased perivascular space volume in white matter and basal ganglia is associated with cognition in Parkinson's Disease.
Donahue EK; Foreman RP; Duran JJ; Jakowec MW; O'Neill J; Petkus AJ; Holschneider DP; Choupan J; Van Horn JD; Venkadesh S; Bayram E; Litvan I; Schiehser DM; Petzinger GM
Brain Imaging Behav; 2024 Feb; 18(1):57-65. PubMed ID: 37855955
[TBL] [Abstract][Full Text] [Related]
3. Altered perivascular spaces in subcortical white matter in Parkinson's disease patients with levodopa-induced dyskinesia.
Cao X; Gan C; Zhang H; Yuan Y; Sun H; Zhang L; Wang L; Zhang L; Zhang K
NPJ Parkinsons Dis; 2024 Mar; 10(1):71. PubMed ID: 38548788
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of perivascular space visualization in basal ganglia and white matter hyperintensity lesion is a meaningful finding for subsequent cognitive decline.
Sugai Y; Hiraka T; Shibata A; Taketa A; Tanae T; Moriya Y; Ohara S; Iseki C; Ohta Y; Kanoto M
Acta Radiol; 2024 Jun; ():2841851241256778. PubMed ID: 38841771
[TBL] [Abstract][Full Text] [Related]
5. The time-course augmentation of perivascular space enlargement in the basal ganglia among a community-dwelling elder population.
Sugai Y; Hiraka T; Shibata A; Taketa A; Tanae T; Moriya Y; Komatsu M; Iseki C; Ohta Y; Kanoto M
Jpn J Radiol; 2024 Jun; ():. PubMed ID: 38896331
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Perivascular Space Morphometry Across the White Matter in Huntington's Disease Using MRI.
Coleman A; Langan MT; Verma G; Knights H; Sturrock A; Leavitt BR; Tabrizi SJ; Scahill RI; Hobbs NZ
J Huntingtons Dis; 2024; 13(1):91-101. PubMed ID: 38517798
[TBL] [Abstract][Full Text] [Related]
7. Utility of Imaging of Nigrosome-1 on 3T MRI and Its Comparison with 18F-DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism.
Kathuria H; Mehta S; Ahuja CK; Chakravarty K; Ray S; Mittal BR; Singh P; Lal V
Mov Disord Clin Pract; 2021 Feb; 8(2):224-230. PubMed ID: 33553492
[TBL] [Abstract][Full Text] [Related]
8. Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
Kang X; Ploner A; Pedersen NL; Bandres-Ciga S; Noyce AJ; Wirdefeldt K; Williams DM
Neurology; 2021 Mar; 96(12):e1672-e1679. PubMed ID: 33608417
[TBL] [Abstract][Full Text] [Related]
9. Association of PSP phenotypes with survival: A brain-bank study.
Guasp M; Molina-Porcel L; Painous C; Caballol N; Camara A; Perez-Soriano A; Sánchez-Gómez A; Garrido A; Muñoz E; Marti MJ; Valldeoriola F; Grau O; Gelpí E; Respondek G; Höglinger GH; Compta Y
Parkinsonism Relat Disord; 2021 Mar; 84():77-81. PubMed ID: 33581485
[TBL] [Abstract][Full Text] [Related]
10. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
[TBL] [Abstract][Full Text] [Related]
11. T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils.
George S; Tyson T; Rey NL; Sheridan R; Peelaerts W; Becker K; Schulz E; Meyerdirk L; Burmeister AR; von Linstow CU; Steiner JA; Galvis MLE; Ma J; Pospisilik JA; Labrie V; Brundin L; Brundin P
J Parkinsons Dis; 2021; 11(2):585-603. PubMed ID: 33579871
[TBL] [Abstract][Full Text] [Related]
12. Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers.
Ma LY; Tian Y; Pan CR; Chen ZL; Ling Y; Ren K; Li JS; Feng T
Front Aging Neurosci; 2020; 12():627199. PubMed ID: 33568988
[No Abstract] [Full Text] [Related]
13. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson's disease: Analysis of the PPMI data.
Lee JW; Song YS; Kim H; Ku BD; Lee WW
PLoS One; 2021; 16(2):e0246881. PubMed ID: 33566871
[TBL] [Abstract][Full Text] [Related]
14. Relevance of Autophagy and Mitophagy Dynamics and Markers in Neurodegenerative Diseases.
Giorgi C; Bouhamida E; Danese A; Previati M; Pinton P; Patergnani S
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33557057
[TBL] [Abstract][Full Text] [Related]
15. Periphery and brain, innate and adaptive immunity in Parkinson's disease.
Harms AS; Ferreira SA; Romero-Ramos M
Acta Neuropathol; 2021 Apr; 141(4):527-545. PubMed ID: 33555429
[TBL] [Abstract][Full Text] [Related]
16. Fine Particle Exposure and Clinical Aggravation in Neurodegenerative Diseases in New York State.
Nunez Y; Boehme AK; Weisskopf MG; Re DB; Navas-Acien A; van Donkelaar A; Martin RV; Kioumourtzoglou MA
Environ Health Perspect; 2021 Feb; 129(2):27003. PubMed ID: 33555200
[TBL] [Abstract][Full Text] [Related]
17. Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease.
Isaacson JR; Brillman S; Chhabria N; Isaacson SH
J Parkinsons Dis; 2021; 11(2):885-889. PubMed ID: 33554925
[TBL] [Abstract][Full Text] [Related]
18. Contribution of coding/non-coding variants in NUS1 to late-onset sporadic Parkinson's disease.
Jiang L; Pan HX; Zhao YW; Zeng Q; Liu ZH; Sun QY; Xu Q; Tan JQ; Yan XX; Li JC; Tang BS; Guo JF
Parkinsonism Relat Disord; 2021 Mar; 84():29-34. PubMed ID: 33548880
[TBL] [Abstract][Full Text] [Related]
19. Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
Song Y; Gong T; Xiang Y; Mikkelsen M; Wang G; Edden RAE
J Neurol Sci; 2021 Mar; 422():117309. PubMed ID: 33548666
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
